FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia

10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Limiting sugar intake could reduce allogeneic hematopoietic cell transplant side effects

Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects.

October 02, 2026

Vol.52 No.36

Cancer Policy

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

This summer, NCI launched a weekly social media series hosted by Director Anthony Letai.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

FDA approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.

September 11, 2026

Vol.52 No.33

Clinical Roundup

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.

August 14, 2026

Vol.52 No.32

FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia

YOU MAY BE INTERESTED IN

10x Genomics and Fred Hutch collaborate to advance single cell and spatial applications across solid tumors and blood cancers

Limiting sugar intake could reduce allogeneic hematopoietic cell transplant side effects

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

Renew today!

Subscriber content

Never miss an issue!

Login